Kimmtrak (Tebentafusp)
Brand Names: Kimmtrak
Methodology & AI Transparency ⓘ
Kimmtrak (Tebentafusp) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Kimmtrak (Tebentafusp) represents a prescription brand-name bispecific gp100 peptide-hla-directed cd3 t cell engager entry registered by Immunocore Commercial LLC with package codes 80446-401.
- 2 Real-world patient consensus: Branded bispecific gp100 peptide-hla-directed cd3 t cell engager presentation of Tebentafusp (Immunocore Commercial LLC); generic reference: /meds/tebentafusp.
- 3 Typical cash cost range: Dispensing cost comparison spans $131.62 mail/discount cash up to $348.79 uninsured retail (federal NADAC $1.7100).
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Kimmtrak (Tebentafusp) include nausea (9.9%), headache (8.5%), fatigue (7.6%).
Ask our AI Specialists anything about Kimmtrak (Tebentafusp)
Kimmtrak (Tebentafusp) Mechanism, CYP450 Pathways & DailyMed Monograph
Kimmtrak (Tebentafusp) represents a prescription brand-name bispecific gp100 peptide-hla-directed cd3 t cell engager entry registered by Immunocore Commercial LLC with package codes 80446-401. Reviewed against 2026-08-20 FDA SPL standards (100 ug/.5mL Injection, Solution, Concentrate; 20 mcg), clinical deployment addresses 1 Indications and usage kimmtrak: is indicated for the treatment of HLA-A*02:01-positive adult patients with unresectable.
Kimmtrak achieves therapeutic action via Tebentafusp, engaging bispecific gp100 peptide-hla-directed cd3 t cell engager physiological pathways with class-characteristic hepatorenal disposition. Manufactured in 100 ug/.5mL Injection, Solution, Concentrate; 20 mcg (registered by Immunocore Commercial LLC, NDC 80446-401), pharmacists evaluate FDA Orange Book therapeutic equivalence when comparing branded Kimmtrak ($348.79 retail) with generic Tebentafusp ($131.62 low cash).
Clinical clearance of Kimmtrak (Tebentafusp) (Bispecific gp100 Peptide-HLA-directed CD3 T Cell Engager) relies on predominantly hepatic biotransformation with renal elimination of polar kimmtrak (tebentafusp) conjugates with a Steady-state plasma equilibrium reached over 3–10 hour t½ intervals for Kimmtrak (Tebentafusp) half-life; patients absorbing at Complete (~100%) parenteral systemic delivery for Kimmtrak (Tebentafusp) (100 ug/.5mL Injection, Solution, Concentrate) bioavailability typically observe target onset around rapid intravascular/parenteral onset within 15–45 minutes after kimmtrak (tebentafusp) administration.
FDA clinical labeling for Kimmtrak (Tebentafusp) restricts administration in contraindicated in patients with prior serious allergic response to kimmtrak (tebentafusp) (ndc 80446-401); severe baseline organ impairment where tebentafusp accumulation exceeds safe therapeutic margins across 100 ug/.5mL Injection, Solution, Concentrate, 20 mcg, 30 mcg, 68 mcg, with self-reported patient tracking dominated by nausea (9.9% of reports), headache (8.5% of reports), fatigue (7.6% of reports).
Reconcile eGFR-adjusted medications before escalating Kimmtrak (Tebentafusp) in polypharmacy regimens.
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Kimmtrak (Tebentafusp) dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Contraindicated in patients with prior serious allergic response to Kimmtrak (Tebentafusp) (NDC 80446-401)
- Severe baseline organ impairment where Tebentafusp accumulation exceeds safe therapeutic margins
Logged Side-Effect Incidence (22 Reports)
Kimmtrak (Tebentafusp) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Kimmtrak (Tebentafusp))
Human clinical trial evidence for Kimmtrak (Tebentafusp) is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Kimmtrak (Tebentafusp) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $1.7100/unit (~$51.30/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $348.79 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 22 Anonymous DotMD Community Micro-Logs | $131.62 / mo | View logs ↓ |
Kimmtrak (Tebentafusp) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Kimmtrak (Tebentafusp) RxNorm Concept ID | 2590754 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $1.7100 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $348.79 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $131.62 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 80.00% Worth It (22 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Kimmtrak (Tebentafusp) Patient Community, Cohort Filters & Dosage Logs
Deterministic Kimmtrak (Tebentafusp) reference combining NIH RxNorm (2590754), Medicaid NADAC ($1.7100/unit), and anonymous cohort outcomes (80% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Kimmtrak (Tebentafusp) community threads and patient logs by age, biological sex, dosage, and treatment duration.